PMVP
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- The New England Journal of Medicine published first-in-human data for rezatapopt demonstrating selective reactivation of mutant p53 in advanced solid tumorsFeb 26, 2026
- PMV Pharmaceuticals announces promising Rezatapopt monotherapy interim data from PYNNACLE Phase 2 trial across multiple solid tumors with TP53 Y220C mutationSep 10, 2025